Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19647652 | 0.80 | CA1 (0.44) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL22667294 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MAPTKMT2AKDM4EHDAC1 | |
| SCHEMBL10153310 | 0.76 | NR4A2 (0.47) | ALDH1A1MAPTNR4A2SMN1; SMN2 | |
| SCHEMBL18468174 | 0.75 | KMT2A (0.43) | ALDH1A1MAPTKMT2AKDM4EPOLB | |
| SCHEMBL30558592 | 0.73 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL395221 | 0.73 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL10277959 | 0.72 | ERN1 (0.31) | MAPTKMT2AKDM4EPOLBMEN1 | |
| SCHEMBL18807913 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KMT2AKDM4EPOLBLMNA | |
| SCHEMBL14095369 | 0.72 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AKDM4EPOLB | |
| SCHEMBL12743719 | 0.71 | ERN1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ALDH1A1 3735/4885MAPT 3420/4885KMT2A 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.